

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 針谷 正祥

雑誌 1 / 3

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	針谷正祥	インフリキシマブ（関節リウマチ-最新治療とガイドライン）	カレントセラピー	22	28-33	2004
2	針谷正祥	TNF阻害療法でなぜ結核は好発するか	臨床免疫	41	430-436	2004
3	針谷正祥	TNF阻害療法の有用性と問題点-TNF阻害薬の適切な使用のために	医学のあゆみ	209	841-846	2004
4	針谷正祥	関節リウマチとその類縁疾患一身につけるべきリウマチ診療の基本とその実践-R A治療のnew standard-生物学的製剤の使い方	Medical Practice	22	in press	2004
5	針谷正祥	変わりゆく膠原病診療-最新治療の光と影-新たな治療法の展望と問題点16. 生物学的製剤	内科	95	in press	2004
6	針谷正祥	目でみるバイオサイエンス 抗TNF- α 抗体の作用機序	内科	95	in press	2004
7	Harigai M., Hara M., Kawamoto M., Kawaguchi Y., Sugiura T., Tanaka M., Nakagawa M., Ichida H., Takagi K., Higami-Ohsako S., Shimada K., Kamatani N	Amplification of the synovial inflammatory response through activation of mitogen-activated protein kinases and nuclear factor kappa-B using ligation of CD40 on CD14+ synovial cells from patients with rheumatoid arthritis.	Arthritis Rheum	50	2167-77	2004
8	針谷正祥	膠原病とCD40-CD154相互作用-病態形成における重要性和新規治療戦略としての可能性-	日本臨床免疫学会会誌	27	379-88	2004
9	針谷正祥	関節リウマチの治療 3)DMARDs e)Tacrolimus	日本臨床	63	508-12	2005
10	針谷正祥	関節リウマチの治療 薬物療法 DMARDs Tacrolimus	日本臨床	63 (Suppl.)	508-512	2005
11	針谷正祥	生物学的製剤 新たな治療法の展望と問題点	内科	95	487-492	2005
12	針谷正祥	RA治療のnew standard -生物学的製剤の使い方-	Medical Practice	22	465-471	2005
13	針谷正祥	抗TNF- α 抗体の作用機序	内科	95	741-744	2005
14	針谷正祥	可溶性TNF受容体の作用機序	内科	95	923-926	2005
15	針谷正祥	CTLA-4-Ig	炎症と免疫	13	312-320	2005
16	針谷正祥	CTLA4-Ig	アレルギーの臨床	25	630-636	2005

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
17	針谷正祥	TNF阻害療法と日和見感染症	最新医学	60	1631-1638	2005
18	針谷正祥	内科外来の「関節痛」の上手な診かた	モダンフィジシャン	25	1172	2005
19	針谷正祥	膠原病の新たな治療、生物学的製剤の展望	日本医事新報	4250	1-9	2005
20	小川 純、針谷正祥	インフリキシマブによるカリニ肺炎の特徴とその対策	リウマチ科	33	485-489	2005
21	Ogawa J, Harigai M, et al.	Prediction of and prophylaxis against <i>Pneumocystis pneumonia</i> in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy	Mod Rheumatol	15	91-96	2005
22	針谷正祥、小池竜司	大学における「薬害監視学講座」の設立。	日本医師会雑誌	134 (11)	2165	2006
23	針谷正祥	ニューモシスチス肺炎	内科	97 (4)	680-683	2006
24	針谷正祥	RAに対するCTLA-4-Ig療法 ー抗CD4モノクローナル抗体との違いは何かー	分子リウマチ	3(2)	149-154	2006
25	針谷正祥	多発性筋炎・皮膚筋炎（特集 内科疾患最新の治療ー専門家からのアドヴァイサー）	内科（増大号）	97 (6)	1222-1223	2006
26	針谷正祥、小池竜司	日本における生物学的製剤の安全性評価とデータベース構築	リウマチ科	35(5)	422-428	2006
27	針谷正祥	免疫抑制薬の種類と使い方。	Medicina	43 (6)	968-970	2006
28	針谷正祥	生物学的製剤と感染症（治療のピットフォール）	治療学	40 (7)	786-787	2006
29	針谷正祥	ACRコアセットを用いた評価（特集 最新の関節リウマチ評価法）。	リウマチ科	36 (3)	237-243	2006
30	針谷正祥	abatacept： T細胞をターゲットにしてなぜ効くのか（特集：関節リウマチのaggressive therapy）	Mebio	23 (12)	83-92	2006
31	宮坂信之、小池竜司、針谷正祥	生物学的製剤を安全に使用するために	整形・災害外科	49 (6)	695-704	2006
32	Kawamoto M, Harigai M, Hara M, et al.	Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-gamma and anti-double-stranded DNA antibody production.	Arthritis Research	8	R62	2006

分担研究者氏名： 針谷 正祥

雑誌 3 / 3

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
33	Ochi S, Harigai M, Mizoguchi F, et al.	Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage.	Mod Rheumatol	16	316-320	2006
34	Ogawa, M Harigai, T Akashi et al.	Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody	Ann Rheum Dis	65	1667-1669	2006

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

主任研究者氏名： 宮坂 信之

雑誌

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	N. Nishimoto, K. Yoshizaki, <u>N. Miyasaka</u> , K. Yamamoto, S. Kawai, T. Takeuchi, J. Hashimoto, J. Azuma, T. Kishimoto	Treatment of rheumatoid arthritis with humanized anti-interleukin 6 receptor antibody : a multicenter, double-blind, placebo-controlled trial.	Arthritis. Rheum.	50(6)	1761-1769	2004
2	T. Nanki, Y. Urasaki, T. Imai, M. Nishimura, K. Muramoto, T. Kubota, <u>N. Miyasaka</u>	Inhibition of fractalkine ameliorates murine collagen-induced arthritis.	J. Immunol.	173 (11)	7010-7016	2004
3	J. Ogawa, M. Harigai, K. Nagasaka, T. Nakamura, <u>N. Miyasaka</u>	Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium-or high-dose corticosteroids therapy.	Mod. Rheumatol.	15(2)	91-96	2005
4	K. Wakamatsu, T. Nanki, <u>N. Miyasaka</u> , K. Umezawa, T. Kubota	Effect of a small molecule inhibitor of nuclear factor- κ B nuclear translocation in a murine model of arthritis and cultured human synovial cells.	Arthritis Res. Therapy	7(6)	R1348-R1359	2005
5	F. Suzuki, T. Nanki, T. Imai, H. Kikuchi, S. Hirohata, H. Kohsaka, <u>N. Miyasaka</u>	Inhibition of CX3CL1(Fractalkine) improves experimental autoimmune myositis in SJL/J mice.	J. Immunol.	175 (10)	6987-6996	2005
6	T. Nanki, T. Shimaoka, K. Hayashida, K. Taniguchi, S. Yonehara, <u>N. Miyasaka</u>	Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis.	Arthritis Rheum.	52(10)	3004-3014	2005
7	<u>N. Miyasaka</u> , T. Takeuchi, K. Eguchi	Guidelines for the proper use of etanercept in Japan.	Mod Rheumatol. Review	16(2)	63-67	2006
8	<u>N. Miyasaka</u>	Etanercept and methotrexate for the treatment of rheumatoid arthritis.	Therapy	3(3)	365-373	2006
9	<u>N. Miyasaka</u>	Issues in the usages of new anti-rheumatic drugs in Japan.	Jap Med Assoc J	49 (5-6)	208-211	2006
10	T. Abe, T. Takeuchi, <u>N. Miyasaka</u> , H. Hashimoto, H. Kondo, Y. Ichikawa, I. Nagaya	A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.	J. Rheumatol.	33(1)	37-44	2006
11	J. Ogawa, M. Harigai, T. Akashi, K. Nagasaka, F. Suzuki, S. Tominaga, <u>N. Miyasaka</u>	Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanized anti-interleukin-6 receptor monoclonal antibody.	Ann. Rheum. Dis.	65 (12)	1667-1669	2006
12	S. Ochi, M. Harigai, F. Mizoguchi, H. Iwai, H. Hagiyaama, T. Oka, <u>N. Miyasaka</u>	Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage.	Mod. Rheumatol.	16(5)	316-320	2006
13	Y. Komano, T. Nanki, K. Hayashida, K. Taniguchi, <u>N. Miyasaka</u>	Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.	Arthritis Res. Ther.	8(5)	R152	2006
14	Y. Nonomura, K. Nagasaka, H. Hagiyaama, C. Sekine, T. Nanki, M. Tamamori-Adachi, <u>N. Miyasaka</u> , H. Kohsaka	Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma protein-dependent and independent pathways by cyclin-dependent kinase 4/6.	Arthritis Rheum.	54(7)	2074-2083	2006
15						
16						

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 田中 良哉

書籍

	著者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
			書籍名	出版地	ページ
1	田中 良哉	関節リウマチに対する抗TNF α 抗体療法の有用性と問題点	宮坂信之、宮島篤編	医歯薬出版	2004
			サイトカイン—state of arts	東京	345-348
2	田中 良哉	関節リウマチ（悪性関節リウマチを含む）	高久文彦、猿田享男、北村惣一郎、福井次夫編	法研	2004
			家庭医学大百科	東京	2907-2911
3	田中 良哉	CD20抗体の自己免疫疾患の治療への応用	岸本忠三編	中山書店	2004
			免疫2005	東京	400-406
4	田中 良哉	抗CD20抗体	宮坂信之編	日本臨床社	2005
			関節リウマチ：成因研究から治療の新时代へ	大阪	544-548
5	田中 良哉	膠原病に於けるシクロスポリン療法	山本一彦編	日本臨床社	2005
			臨床免疫学（下）—基礎研究の進歩と最新の臨床	大阪	240-246
6	田中 良哉	抗CD20抗体	山本一彦編	日本臨床社	2005
			臨床免疫学（下）—基礎研究の進歩と最新の臨床	大阪	728-733
7	田中 良哉	関節リウマチの診断基準・病型分類・重症度	内科編集室編	南江堂	2005
			内科疾患の診断基準・病型分類・重症度	東京	1432-1437
8	田中良哉、岡田洋右	ステロイド性骨粗鬆症とは	田中良哉編	医薬ジャーナル社	2005
			ステロイド骨粗鬆症のマネジメント	大阪	9-15
9	田中 良哉	全身性エリテマトーデス	宮坂信之編	最新医学社	2005
			免疫と疾患（後篇）—自己免疫と疾患	大阪	119-126
10	田中 良哉	全身性エリテマトーデス	富野康日己編	中外医学社	2005
			内科疾患診療マニュアル	東京	739-744
11	田中 良哉	シェーグレン症候群	山口徹、北原光夫編	医学書院	2006
			今日の治療指針 2006年版—私はこう治療している	東京	600-602
12	田中 良哉	細胞認識と接着分子	金澤一郎、北原光夫、山口徹、小俣政男編	医学書院	2006
			内科学	東京	54-58
13	田中 良哉	血管炎症候群	山口徹、北原光夫、福井次夫編	医学書院	2007
			今日の治療指針 2007年版—私はこう治療している	東京	589-591

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 田中 良哉

雑誌

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	Nakayamada S, Okada S, Saito K, Tanaka Y.	Etidronate prevents high-dose glucocorticoid-induced bone loss in premenopausal individuals with systemic autoimmune diseases.	J Rheumatol	31	163-166	2004
2	Saito K, Nakayamada S, Nakano K, Tokunaga M, Tsujimura S, Nakatsuka K, Adachi T, Tanaka Y.	Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: Reevaluation of clinical features of P. carinii pneumonia in rheumatic diseases.	Rheumatology	43	479-485	2004
3	Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y.	Macrophage inflammatory protein-1 α induces hypercalcemia in adult T-cell leukemia.	J Bone Miner Res	19	1105-1111	2004
4	Nakano K, Okada Y, Saito K, Tanaka Y.	Fibroblast growth factor-2 induces receptor activator of nuclear factor kappa B ligand expression and osteoclast maturation by binding to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts.	Arthritis Rheum	50	2450-2458	2004
5	Tanikawa T, Okada Y, Azuma T, Fukushima A, Kawahara C, Tanaka Y.	Adult-onset idiopathic progressive acroosteolysis with proximal symphalangism.	J Bone Miner Res	19	165-167	2004
6	Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.	Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.	Rheumatology	44	176-182	2005
7	Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y.	Clinical relevance of expression of P-glycoprotein on peripheral lymphocytes to steroid-resistance in systemic lupus erythematosus.	Arthritis Rheum	52	1676-1683	2005
8	Saito K, Nawata M, Iwata S, Tokunaga M, Tanaka Y.	Extremely high titre of antihuman chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus.	Rheumatology	44	1462-1464	2005
9	Nakayamada S, Kurose K, Saito K, Mogami A, Tanaka Y.	Small GTP-binding protein rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts.	Arthritis Res Ther	7	476-484	2005
10	Sakuma-Zenke M, Sakai A, Nakayamada S, Kunugita N, Uchida S, Tanaka S, Mori T, Tanaka Y, T Nakamura.	Reduced expression of platelet endothelial cell adhesion molecule-1 in bone marrow cells in mice after unloading.	J Bone Miner Res	20	1002-1010	2005
11	Tsujimura S, Saito K, Kohno K, Tanaka Y.	Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+ T cells.	J Biol Chem	281	38089-97	2006
12	Tanaka Y, Tokunaga M.	Rituximab reduces both quantity and quality of B cells in SLE.	Rheumatology	45	122-123	2006
13	Tsukamoto H, Nagafuji K, Horiuchi T, Miyamoto T, Aoki K, Takase K, Henzan H, Himeji D, Koyama T, Miyake K, Inoue Y, Nakashima H, Otsuka T, Tanaka Y, Nagasawa K, Harada M.	A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease.	Ann Rheum Dis	65	508-514	2006
14	Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, Tsujimura S, Nawata M, Iwata S, Azuma T, Mimori T, Tanaka Y.	Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.	Ann Rheum Dis		in press	
15	Nakano K, Okada Y, Saito K, Tanikawa R, Sawamukai N, Sasaguri Y, Kohro T, Wada Y, Kodama M, Tanaka Y.	Rheumatoid synovial endothelial cells produce macrophage-colony stimulating factor leading to osteoclastogenesis in rheumatoid arthritis.	Rheumatology		in press	
16	Nakayamada S, Saito K, Nakano K, Tanaka Y.	β 1 integrin transduces an activation signal in T cells of patients with systemic lupus erythematosus.	Arthritis Rheum		in press	

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 當間 重人

書籍

	著者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
			書籍名	出版地	ページ
1	松井利浩、當間重人	VII. 特論「診療・研究支援システム」 関節リウマチー成因研究から治療の時代へー	宮坂信之	日本臨床社	2005
			日本臨床	東京	699-705
2	當間重人	RAの病像と診断 ーいつどのようにしてRAの診断を下すのかー	矢崎義雄	文光堂	2005
			Medical Practisce	東京	387-390
3	當間重人	薬物療法	越智隆弘	金原出版	2005.3
			NEW MOOK 整形外科	東京	292-301
4	當間重人	特集<薬物アレルギーとその周辺> レフルノミドによる肺障害	黒沢元博	タイユ	2005
			Topics in Atopy	東京	34-39
5	當間重人	薬物療法の実際 治療戦略	川合眞一	日本医事新報社	2005
			慢性疾患薬物療法のツボ 「関節リウマチ」	東京	107-115
6	中山久徳、萩原太、當間重人	関節リウマチ患者における薬物療法の効果	折茂 肇	サイフサイエンス出版	2006
			Osteoporosis Japan	東京	13-18
7	當間重人	関節リウマチと間質性肺病変ー血清マーカーを中心にー	リウマチ科編集委員会	科学評論社	2006
			リウマチ科	東京	30-30
8					
9					
10					
11					
12					
13					

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 當間 重人

雑誌

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	Matsui T, Ohsumi K, Sumitomo S, Shimane K, Watanabe J, Shimada K, Nakayama H, Sugii S, Ozawa Y, <u>Tohma S</u>	Clinical utility of the quantitative measurements of CD64 on neutrophils to distinguish infection from a flare of rheumatoid arthritis.	Arthritis & Rheumatism	50(9)	S163	2004
2	Nakayama H, Hagiwara F, <u>Tohma S</u> .	Bone Mineral Density and Frequency of Osteoporosis and Vertebral Fractures in Japanese Patients with Rheumatoid Arthritis.	Arthritis & Rheumatism	50(9)	S 498	2004
3	Nakayama H, Hagiwara F, <u>Tohma S</u> .	The Efficacy of Alendronate, Risedronate and Etidronate in Treatment of Osteoporosis and Reducing the Risk for Vertebral Fractures of Rheumatoid Arthritis Patients (fracture intervention trial).	Arthritis & Rheumatism	50(9)	S 498	2004
4	Matsui T, Shimada K, <u>Tohma S</u> .	Anti-cyclic citrullinated peptide antibody in rheumatic diseases other than rheumatoid arthritis.	Clin Rheumatol [Epub ahead of print]	Nov 10;1-2		2005
5	Shimada K, Matsui T, Kuga Y, Nishino J, Takemura M, Ozawa N, Nakayama H, Sugii S, Ozawa Y, <u>Tohma S</u> .	Serum Cartilage Oligomeric Matrix Protein (COMP) Level as a Prediction Marker for Joint Destruction in Japanese Patients of Early Rheumatoid Arthritis (RA) before Anti-Rheumatic Treatment.	Arthritis & Rheumatism	52	S125	2005
6	Matsui T, Ohsumi K, Ozawa N, Shimada K, Sumitomo S, Shimane K, Kawakami M, Nakayama H, Sugii S, Ozawa Y, <u>Tohma S</u> .	CD64 on Neutrophils is a Sensitive and Specific Marker for Detection of Infection in Patients with Rheumatoid Arthritis.	Jornal of Rheumatology	33	2416-24	2006
7	Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H, Sugii S, Ozawa Y, <u>Tohma S</u> .	Diagnostic Utility of Anti-Cyclic Citrullinated Peptide Antibodies for Very Early Rheumatoid Arthritis.	Jornal of Rheumatology	33	2390-7	2006
8	Shimada K, Matsui T, Kawakami M, Nakayama H, Ozawa Y, Mitomi H and <u>Tohma S</u> .	Met hotrexate-related Lymphomatoid Granulomatosis: A Case Report of Spontaneous Regression of Large Tumors in Multiple Organs After Cessation of Methotrexate Therapy in Rheumatoid Arthritis.	Scand J Rheumatol	in press		
9	Matsui T, Shimada K, <u>Tohma S</u> .	Anti-cyclic citrullinated peptide antibody in rheumatic di seases other than rheumatoid arthritis.	Clin Rheumatol.	Jul; 25(4)	610-1	2006
10	Yamanaka H, <u>Tohma S</u> .	Potential impact of observational cohort sutudies in Japan on rh eumatoid arthritis research and practice.	Mod Rheumatol	16	75-76	2006
11						
12						
13						
14						
15						
16						

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 井田 弘明

雑誌

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	Aramaki T, Ida H, Izumi Y, Huang M, Arima K, Fujikawa K, Iwanaga N, Aratake K, Tamai M, Kamachi M, Nakamura H, Origuchi T, Kawakami A, Matsuoka N, Eguchi K.	Alteration of natural killer (NK) cell activity in patients with rheumatoid arthritis treated by biologic agents.	APLAR J Rheumatol.	9巻 supl 1	A192	2006
2	Izumi Y, Ida H, Huang M, Iwanaga N, Tanaka F, Aratake K, Arima K, Tamai M, Kamachi M, Nakamura H, Origuchi T, Kawakami A, Anderson F, Eguchi K.	Characterization of peripheral natural killer cells in primary Sjögren's syndrome: impaired NK cell activity and low NK cell number.	J Lab Clin Med.	147巻5 号	242-249	2006
3	Izumi Y, Ida H, Huang M, Iwanaga N, Tanaka F, Aratake K, Arima K, Tamai M, Kamachi M, Nakamura H, Origuchi T, Kawakami A, Anderson F, Eguchi K.	Mechanisms of impaired natural killer cell activity in primary Sjögren's syndrome: involvement of low NK cell number and low expression of NK cell activating receptors.	Ann Rheum Dis.	64巻 supl 3	310	2006
4	Ida H, Utz PJ, Anderson P, Eguchi K.	Granzyme B and NK cell death.	Modern Rheum.	15巻 5号	315-322	2005
5	Huang M, Ida H, Kamachi M, Iwanaga N, Izumi Y, Tanaka F, Aratake K, Arima K, Tamai M, Hida A, Nakamura H, Origuchi T, Kawakami A, Ogawa N, Sugai S, Utz PJ, Eguchi K.	Detection of apoptosis-specific autoantibodies directed against granzyme B-induced cleavage fragments of the SS-B (La) autoantigen in sera from patients with primary Sjögren's syndrome.	Clin Exp Immunol.	142巻 10号	148-154	2005
6	井田弘明、和泉泰衛、黄明園、有馬和彦、江口勝美	アポトーシスによる新たな組織障害機構：グランザイムBの役割	リウマチ科	34巻 4号	416-425	2005
7	Ida H, Kawasaki E, Miyashita T, Tanaka F, Kamachi M, Izumi Y, Huang M, Tamai M, Origuchi T, Kawakami A, Migita K, Motomura M, Yoshimura T, Eguchi K.	A novel mutation (I61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus.	Rheumatology (Oxford)	43巻10 号	1292-9	2004
8	Kawakami A., Urayama S., Yamasaki S., Hida A., Miyashita T., Kamachi M., Nakashima K., Tanaka F., Ida H., Kawabe Y., Aoyagi T., Furuichi I., Migita K., Origuchi T., Eguchi K.	Anti-apoptogenic function of TGFbeta1 for human synovial cells: TGFbeta1 protects cultured synovial cells from mitochondrial perturbation induced by several apoptogenic stimuli	Ann Rheum Dis	63巻 1号	95-7	2004
9	Migita K., Miyashita T., Ishibashi H., Maeda Y., Nakamura M., Yatsushashi H., Ida H., Kawakami A., Aoyagi T., Kawabe Y., Eguchi K.	Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts	Clin Exp Immunol	137巻3 号	612-6	2004
10	Miyashita T., Kawakami A., Nakashima T., Yamasaki S., Tamai M., Tanaka F., Kamachi M., Ida H., Migita K., Origuchi T., Nakao K., Eguchi K.	Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells	Clin Exp Immunol	137巻2 号	430-6	2004
11	Tanaka F., Migita K., Kawabe Y., Aoyagi T., Ida H., Kawakami A., Eguchi K.	Interleukin-18 induces serum amyloid A (SAA) protein production from rheumatoid synovial fibroblasts	Life Sci	74巻13 号	1671-9	2004
12	Yamasaki S., Nakashima T., Kawakami A., Miyashita T., Tanaka F., Ida H., Migita K., Origuchi T., Eguchi K.	Cytokines regulate fibroblast-like synovial cell differentiation to adipocyte-like cells	Rheumatology (Oxford)	43巻 4号	448-52	2004
13						
14						
15						
16						

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 西本 憲弘

書籍

	著者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
			書籍名	出版地	ページ
1	Nishimoto N, Kishimoto T.	Is IL-6 a therapeutic target?	Van den Berg W.B, Miossec P, eds.	Birkhäuser Verlag	2004
			Progress in Inflammation Research.	Basel	89-106
2	西本憲弘	抗IL-6レセプター抗体 (MRA)による IL-6阻害治療	七川敬次 監修	永井書店	2005
			リウマチ病セミナーXV	大阪府	171-176
3	西本憲弘	トシリズマブ	川合眞一編	南江堂	2006
			抗リウマチ薬の選び方と使い方	東京都	101-106
4					
5					
6					
7					
8					
9					
10					
11					
12					
13					

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 西本 憲弘

雑誌 1 / 2

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, <u>Nishimoto N</u> , Yoshizaki K, Shimoyama T, Kishimoto T.	A Pilot Randomized Trial of a Human Anti-Interleukin-6 Receptor Monoclonal Antibody in Active Crohn's Disease.	Gastroenterol.	126	989-996	2004
2	<u>Nishimoto N</u> , Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T.	Treatment of Rheumatoid Arthritis with Humanized Anti-interleukin 6 Receptor Antibody.	Arthritis Rheum.	50	1761-1769	2004
3	<u>Nishimoto N</u> , Kishimoto T.	Inhibition of IL-6 for the treatment of inflammatory diseases.	Curr. Opin Pharmacol	4	386-391	2004
4	Mihara M, Shiina M, <u>Nishimoto N</u> , Yoshizaki K, Kishimoto T, Akamatsu K.	Anti-interleukin-6 receptor antibody inhibits murine AA-amyloidosis.	J. Rheumatol.	31	1132-1138	2004
5	Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, <u>Nishimoto N</u> , Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF.	TGF- β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.	Immunity.	21	491-501	2004
6	Kunitomi A, Konaka Y, Yagita M, <u>Nishimoto N</u> , Kishimoto T, Takatsuki K.	Humanized anti-interleukin-6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia.	Int. J. Hematol.	80	246-249	2004
7	Dogenci A, Eigenbrod T, Krug N, De Santis GT, Hausding M, Erpenbeck VJ, Haddad B, Bopp T, Kallen KJ, Herz U, Schmitt S, Luft C, Hecht O, Hohlfeld M, <u>Nishimoto N</u> , Yoshizaki K, Kishimoto T, Rose-John S, Benz H, Neurath MF, Galle PR, Finotto S.	The IL-6 α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.	J. Clin. Invest.	115	313-325	2005
8	Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, <u>Nishimoto N</u> , Yoshizaki K, Kishimoto T.	Therapeutic Efficacy of Humanized Recombinant Anti-IL 6-Receptor Antibody for Children with Systemic-Onset Juvenile Idiopathic Arthritis.	Arthritis Rheum	52	818-825	2005
9	Mihara M, <u>Nishimoto N</u> , Ohsugi Y.	Effect of anti-mouse interleukin-6 receptor antibody in autoimmune mouse models.	Prog. in Monoclon. Antibody Res.		151-162	2005
10	<u>Nishimoto N</u> .	Clinical study in patients with Castleman's disease, Crohn's disease and rheumatoid arthritis in Japan.	Clin. Rev. in Allergy and Immunol.	28	221-229	2005
11	Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, <u>Nishimoto N</u> , Yoshizaki K, Kishimoto T.	Therapeutic Efficacy of Humanized Recombinant Anti-IL 6-Receptor Antibody for Children with Systemic-Onset Juvenile Idiopathic Arthritis.	Arthritis Rheum	52	818-825	2005
12	Mihara M, <u>Nishimoto N</u> , Ohsugi Y	The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.	Expert Opin. Biol. Ther	5	683-690	2005
13	<u>Nishimoto N</u> .	Clinical study in patients with Castleman's disease, Crohn's disease and rheumatoid arthritis in Japan.	Clin. Rev. in Allergy and Immunol	28	221-230	2005
14	<u>Nishimoto N</u> , Kanekura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Saeki T, Nishioke K, Hara M, Taguchi H, Kimura Y, Rito Y, Aseoku H, Kumagai S, Kodama F, Nakahara H, Hagiwara K, Yoshizaki K, Kishimoto T	Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease.	Blood	106	2627-2632	2005
15	Nakahara H, <u>Nishimoto N</u> .	Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.	Endocr Metab Immune Disord Drug Targets	6	373-81	2006
16	<u>Nishimoto N</u> , Kishimoto T.	Interleukin 6: from bench to bedside.	Nat Clin Pract Rheumatol	2	619-26	2006

分担研究者氏名： 西本 憲弘

雑誌 2 / 2

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
17	Straub RH, Harle P, Yamana S, Matsuda T, Takasugi K, Kishimoto T, <u>Nishimoto N</u>	Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized double-blind placebo-controlled study.	Arthritis Rheum	54	1778-85	2006
18	<u>Nishimoto N</u> .	Interleukin-6 in rheumatoid arthritis.	Curr Opin Rheumatol	18	277-81	2006

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 石ヶ坪 良明

雑誌

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	H. Ideguchi, S. Ohno, A. Ueda, <u>Y. Ishigatsubo</u>	Catastrophic antiphospholipid syndrome associated with malignancies.	Lupus	16	59-64	2007
2	Y. Kirino, M. Takeno, S. Murakami, M. Kobayashi, H. Kobayashi, K. Miura, H. Ideguchi, S. Ohno, A. Ueda, <u>Y. Ishigatsubo</u>	Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes.	Arthritis Rheum	56	464-475	2007
3	H. Ideguchi, S. Ohno, <u>Y. Ishigatsubo</u>	A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection.	Rheumatol Int.	27	411-414	2007
4	M. Takeno, <u>Y. Ishigatsubo</u>	Behcet's disease and familial Mediterranean fever.	Intern Med.	45	805-806	2006
5	S. Ohno, <u>Y. Ishigatsubo</u>	The incidence of Lofgren's syndrome in Japanese: the number of patients affected, number of patients diagnosed and number of cases reported.	Intern Med.	45	745-746	2006
6	R. Yoshimi, M. Takeno, S. Yamanaka, M. Shina, Y. Kirino, Y. Takeda, A. Sekiguchi, H. Kobayashi, A. Ihata, K. Motuji, S. Ohno, A. Ueda, T. Soga, <u>Y. Ishigatsubo</u>	Systemic sclerosis and pseudomesotheliomatous adenocarcinoma of the lung.	Mod Rheumatol.	16	165-168	2006
7	H. Ideguchi, S. Ohno, A. Senuma, H. Hattori, <u>Y. Ishigatsubo</u>	Bone erosions in rheumatoid arthritis can be repaired through reduction in disease activity with conventional disease-modifying antirheumatic drugs.	Arthritis Res Ther.	8	R76	2006
8	H. Kobayashi, M. Takeno, T. Saito, Y. Takeda, Y. Kirino, K. Noyori, T. Hayashi, A. Ueda, <u>Y. Ishigatsubo</u>	Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis.	Arthritis Rheum.	54	1132-1142	2006
9	R. Yoshimi, S. Yamaji, A. Suzuki, W. Mishima, M. Okamura, T. Obana, C. Matsuda, Y. Miwa, S. Ohno, <u>Y. Ishigatsubo</u>	The gamma-parvin-integrin-linked kinase complex is critically involved in leukocyte-substrate interaction.	J Immunol.	176	3611-3624	2006
10	M. Takeno, <u>Y. Ishigatsubo</u>	Intestinal manifestations in systemic lupus erythematosus.	Intern Med.	45	41-42	2006
11	Y. Yamaguchi, S. Ohno, S. Yamazaki, H. Ideguchi, A. Shirai, M. Takeno, <u>Y. Ishigatsubo</u>	A case of systemic lupus erythematosus complicated with pneumatosis cystoides intestinalis.	Mod Rheumatol.	15	440-444	2005
12	Y. Kirino, M. Takeno, S. M. Iwasaki, A. Ueda, S. Ohno, A. Shirai, H. Kanamori, K. Tanaka, <u>Y. Ishigatsubo</u>	Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia.	Arthritis Res Ther.	7	R616-624	2005
13	T. Kaneko, <u>Y. Ishigatsubo</u>	Isoniazid and food interactions: —fish, cheese, and wine.	Intern Med.	44	1120-1121	2005
14	S. Kagami, M. Shimizu, S. Kondo, A. Kitamura, M. Urushihara, M. Takamatsu, S. Yamaji, <u>Y. Ishigatsubo</u> , H. Kawachi, F. Shimizu.	Up-regulation of integrin-linked kinase activity in rat mesangioproliferative glomerulonephritis.	Life Sci.	78	1794-1800	2005
15						
16						

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 小池 隆夫

書籍

	著者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
			書籍名	出版地	ページ
1	Atsumi,T.,Matsura,E.,Koike,T	Immunology of antiphospholipid antibodies and co-factors.	Lahita RG	Academic Press	2004
			Systemic Lupus Erythematosus 4th edition	San Diego	1081-1105
2					
3					
4					
5					
6					
7					
8					
9					
10					
11					
12					
13					

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 小池 隆夫

雑誌 1 / 3

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	Li,N., Nakamura,K., Jiang,Y., Tsurui,H., Matsuoka,S., Abe,M., Ohtsui,M., Nishimura,H., Kato,K., Kawai,T., Atsumi,T., <u>Koike.T.</u> , Shirai,T., Ueno,H., Hirose,S.	Gain-of-function polymorphism in mouse and human Ltk: implications for the pathogenesis of lupus erythematosus.	Hum Mol Genet	13	171-179	2004
2	Endo,T., Nakao,S., <u>Koizumi,K.</u> , Nishio,M., Fujimoto,K., Sakai,T., Kuwano,K., Obara,M., <u>Koike.T.</u>	Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-non myeloblastic stem cell transplant patient.	Ann Hematol	83	114-116	2004
3	<u>Koizumi,K.</u> , Fujimoto,K., Haseyama,Y., Endo,T., Nishio,M., Yokota,K., Itoh,K., Sawada,K., <u>Koike.T.</u>	Effective high-dose chemotherapy combined with CD34+ selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/T-cell lymphoma.	Eur J Haematol.	72	140-144	2004
4	Yamamoto,S., Tsuji,T., Matsuzaki,J., Zhang,Y., Chamoto,K., Kosaka,A., Togashi,Y., Sekikawa,K., Sawada,K., Takeshima,T., <u>Koike.T.</u>	Nishimura,T.: Unexpected role of TNF- α in graft versus host reaction (GVHR): donor-derived TNF- α suppresses GVHR via inhibition of IFN- γ -dependent donor type-1 immunity.	Int Immunol.	16	811-817	2004
5	Endo,T., Mogi,Y., <u>Koizumi,K.</u> , Nishio,M., Fujimoto,K., Sakai,T., Kumano,K., Obara,M., Ikeda,H., <u>Koike.T.</u>	Peripheral blood stem cell mobilization following plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma.	Bone Marrow Transplant.	33	703-707	2004
6	Yasuda,S., Atsumi,T., Ieko,M., Matsuura,E., Kobayashi,K., Inagaki,J., Kato,H., Tanaka,H., Yamakado,M., Akino,M., Saitou,H., Amasaki,Y., Jodo,S., Amengual,O., <u>Koike.T.</u>	Nicked β 2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis.	Blood	103; 10	3766-3772	2004
7	Yasuda,S., Ogura,N., Horita,T., Yasuda,I., Hloka,T., Kondo,N., Fujisaku,A.	Abacterial prostatitis and primary biliary cirrhosis with Sjogren's syndrome.	Mod Rheumatol	14	70-72	2004
8	Das,H., Atsumi,T., Fukushima,Y., Shibuya,H., Ito,K., Yamada,Y., Amasaki,Y., Ichikawa,K., Amengual,O., <u>Koike.T.</u>	Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis.	Clin Rheumatol	23	218-222	2004
9	Ieko,M., Tarumi,T., Takeda,M., Nito,S., Nakabayashi,T., <u>Koike.T.</u>	Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.	J Thromb Haemost	2	612-622	2004
10	Amengual,O., Atsumi.T., <u>Koike.T.</u>	Antiprothrombin antibodies and the diagnosis of antiphospholipid syndrome.	Clin Immunol	112	144-149	2004
11	Endo,T., <u>Koizumi,K.</u> , Nishio,M., Fujimoto,K., Sakai,T., Kumano,K., Obara,M., Minauchi,K., <u>Koike.T.</u>	Localized relapse in bone marrow of extremities after allogenic stem cell transplantation for acute lymphoblastic leukemia.	Am J Hematol	76	279-282	2004
12	Yang,L., Hakoda,M., Iwabuchi,K., Takeda,T., <u>Koike.T.</u> , Kamatani.N., Takeda.K.	Rheumatoid Factors Induce Signaling from B cells, leading to Epstein-Barr virus and B-cell activation.	J Virol	78 ; 18	9918-9923	2004
13	Kataoka,H., <u>Koike.T.</u>	Lupus mortality in Japan.	Autoimmunity Reviews	3	421-422	2004
14	Endo,T., Sato,N., <u>Koizumi,K.</u> , Nishio,M., Fujimoto,K., Yamamoto,S., Sakai,T., Bohgaki,T., Sawada,K., <u>Koike.T.</u>	A preliminary analysis of the balance between Th1 and Th2 cells after CD34+ cell-selected autologous PBSC transplantation.	Cytotherapy	6 ; 4	337-343	2004
15	Xiao,S., Deshmukh,S.U., Jodo,S., <u>Koike.T.</u> , Sharma,R., Furusaki,A., Sung J.S., Ju, Shyr-Tu	Novel negative regulator of expression in Fas Ligand(CD178)Cytoplasmic tail:Evidence for Translational Regulation and against Fas Ligand Retention in secretory lysosomes.	J Immunol	173	5095-5102	2004
16	Yasuda,S., Atsumi,T., Ieko,M., <u>Koike.T.</u>	β 2-glycoprotein I, anti- β 2-glycoprotein I, and fibrinolysis.	Thromb Res	114	461-465	2004

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
17	Astumi,T.,Amengual,O.,Yasuda,S., Koike,T.	Antiprothrombin antibodies—are they worth assaying?	Thromb Res	114	533-538	2004
18	Bohgaki,M.,Atsumi,T.,Yamashita,Y.,Yasuda,S.,Sakai,Y.,Furusaki,A.,Bohgaki,T.,Amengual,O.,Amasaki,Y.,Koike,T.	The p38 mitogen-activated protein kinase(MAPK)pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2Glycoprotein I antibodies.	Int Immunol	16 ; 11	1633-1641	2004
19	Sugiura-ogasawara.M.,Atsumi,T.,Ozaki,Y.,Koike.T.,Suzumori,K	Phosphatidylserine-dependent antiprothrombin antibodies are not useful markers for high-risk woman with recurrent miscarriages.	Fertil Steril	82	51440-1442	2004
20	Yasuda,S.,Atsumi,T.,Matsuura,E.,Kaiharu.K.,Yamamoto,D.,Ichikawa,K.,Koike.T	Significance of valine/leucine ³³ polymorphism of β2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-β2-glycoprotein I autoantibodies to the valine ³³ β2-glycoprotein I variant	Arthritis Rheum	52 ; 1	212-218	2005
21	Kataoka,H.,Takahashi,S.,Takase,K.,Yamasaki,S.,Yokosuka,T.,Koike,T.,Saito,T	CD25 ⁺ CD4 ⁺ regulatory T cells exert in vitro suppressive activity independent of CTLA-4.	Int Immunol	17 ; 4	421-427	2005
22	Jodo,S.,Pidiyar,VJ.,Xiao,S.,Furusaki,A.,Sharma,R.,Koike.T.,Ju,ST.	Fas Ligand (CD178) Cytoplasmic Tail Is a Positive Regulator of Fas Ligand-Mediated Cytotoxicity.	J Immunol	174	4470-4474	2005
23	Kochi,Y.,Yamada,R.,Suzuki,A.,Herley JB.,Shirawawa,S.,Sawada,T.,Bee,SC.,Tokuhito,S.,Chang,K.,Sekine,A.,Takahashi,A.,Tsunoda,T.,Oishi,T.,Kudoh,H.,Kang CP.,Hwang,C.,Ozuba,S.,Yumura,W.,Mimori,A.,Kikuchi,T.,Nakamura,Y.,Suzuki,T.,Yamamoto,K.	A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities.	Nat Genet	37 ; 5	478-485	2005
24	Imai,Y.,Chou,T.,Tobinai,K.,Tanosaki,R.,Morishima,Y.,Ogura,M.,Shimazaki,C.,Taniwaki,M.,Hiraoka,A.,Tanimoto,M.,Koike.T.,Kogawa,K.,Hirai,H.,Yoshida,T.,Tamura,K.,Kishi,K.,Hotta,T	CliniMACS Study Group. Isolation and transplantation of highly purified autologous peripheral CD34 ⁺ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study.	Bone Marrow Transpl	35 ; 5	479-487	2005
25	Atsumi,T.,Furukawa,S.,Amengual,O.,Koike.T.	Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis.	Lupus	14	499-504	2005
26	Bohgaki,T., Amasaki,Y., Nishimura,N., Bohgaki,M., Yamashita,Y., Nishio,M., Sawada,KI., Jodo,S., Atsumi,T., Koike.T	Up regulated expression of tumour necrosis factor α converting enzyme in peripheral monocytes of patients with early systemic sclerosis.	Ann Rheum Dis.	64	1165-1173	2005
27	Atsumi,T., Amengual,O., Yasuda,S., Matsuura,E., Koike.T.	Research around β2-glycoprotein I: A major target for antiphospholipid antibodies.	Autoimmunity	38(5)	377-381	2005
28	Fukae,J.,Amasaki,Y.,Yamashita,Y.,Bohgaki,T.,Yasuda,S.,Jodo,S.,Atsumi,T.,Koike.T.	Butyrate suppresses tumor necrosis factor α production by regulating specific messenger RNA degradation mediated through a cis-acting AU-rich element.	Arthritis Rheum.	52(9)	2697-2707	2005
29	Koike.T., Atsumi,T.	Antiphospholipid antibodies and cell activation: crucial role of p38 MAPK pathway.	Lupus	14(10)	799-801	2005
30	Atsumi,T.,Nisho,T.,Niwa,H.,Takeuchi,J.,Bando,H.,Shimizu,C.,Yoshioaka,N.,Bucala,R.,Koike.T.	Expression of inducible 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase/PFKFB3 isoforms in adipocytes and their potential role in glycolytic regulation.	Diabetes	54(12)	3349-3357	2005
31	Kasahara,H.,Matsuura,E.,Kaiharu,K.,Yamamoto,D.,Kobayashi,K.,Inagaki,J.,Ichikawa,K.,Tsutsumi,A.,Yasuda,S.,Atsumi,T.,Yasuda,T.,Koike.T.	Antigenic structures recognized by anti-β2-glycoprotein I auto-antibodies.	Int immunol	17(12)	1533-1542	2005
32	Yasuda,S.,Bohgaki,M.,Atsumi,T.,Koike.T.	Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway.	Immunobiology	210	775-780	2005
33	Nakabayashi,T.,Mizukami,K.,Naitoh,S.,Takeda,M.,Shikamoto,Y.,Nakagawa,T.,Kaneiko,H.,Tarumi,T.,Mizoguchi,I.,Mizuno,H.,Ieko,M.,Koike.T.	Protein C Sapporo (protein C Glu 25 →Lys):A heterozygous missense mutation in the Gla domain provides new insight into the interaction between protein C and endothelial protein C receptor.	Thromb Haemost	94	942-950	2005

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
34	Nishio, M., Endo, T., Fujimoto, K., Sato, N., Sakai, T., Obara, M., Kumano, K., Minauchi, K., Koike, T.	Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia.	Eur J Haematol.	75(6)	527-529	2005
35	Ieko, M., Tarumi, T., Nakabayashi, T., Yoshida, M., Naito, S., Koike, T.	Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.	Frontiers in Bioscience	11	232-248	2005
36	Koike T, Atsumi T.	"Resurrection of Thrombin" in the pathophysiology of the antiphospholipid syndrome.	Arthritis Rheum.	in press		
37	Minauchi K, Nishio M, Itoh T, Yamamoto S, Fujimoto K, Sato N, Koike T.	Hepatosplenic alpha/beta T cell lymphoma presenting with cold agglutinin disease.	Ann Hematol.	86(2)	155-157	2007
38	Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHW, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Kritis SA.	International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome.	J Thromb Haemost	4	295-306	2006
39	Mizumoto H, Maihara T, Hiejima E, Shiota M, Hata A, Seto S, Atsumi T, Koike T, Hata D.	Transient antiphospholipid antibodies associated with acute infections in children: a report of three cases and a review of the literature.	Eur J Pediatr	165	484-488	2006
40	Nakamura A, Shimizu C, Nagai S, Taniguchi S, Umetsu M, Atsumi T, Wada N, Yoshioka N, Ono Y, Tanizawa Y, Koike T	A novel mutation of <i>WFS1</i> gene in a Japanese man of Wolfram syndrome with positive diabetes-related antibodies.	Diabetes Res Clin Pract.	73(2)	215-217	2006
41	Nagai S, Shimizu C, Kimura Y, Umetsu M, Taniguchi S, Takeuchi J, Atsumi T, Yoshioka N, Kubo M, Koike T.	A case of reversed pituitary dysfunction with intrasellar mass.	J Endocrinol Invest.	29(4)	367-372	2006
42	Amengual O, Atsumi T, Koike T.	Pathophysiology of the antiphospholipid syndrome: roles of anticardiolipin antibodies in thrombosis and fibrinolysis.	APLAR J Rheumatol.	9	377-386	2006
43	Mizukami K, Nakabayashi T, Naitoh S, Takeda M, Tarumi T, Mizoguchi I, Ieko M, Koike T	One novel and one recurrent mutation in the <i>FROS1</i> gene cause type I protein S deficiency in patients with pulmonary embolism associated with deep vein thrombosis.	Am J Hematol	81	787-797	2006
44	Ieko M, Tarumi T, Nakabayashi T, Yoshida M, Naito S, Koike T.	Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.	Frontiers in Bioscience.	11	232-248	2006
45	Furusaki A, Judo S, Yamashita Y, Amasaki Y, Atsumi T, Koike T.	TRAIL-mediated cytotoxicity: Impacts of sTRAIL and vTRAIL microvesicles.	J Biol Sci.	6 (1)	150-159	2006
46	Niwa H, Koumoto C, Shiga T, Takeuchi J, Mishima S, Segawa T, Atsumi T, Shimizu C, Koike T, Yoshioka N.	Clinical analysis of cognitive function in diabetic patients by MMSE and SPECT.	Diabetes Res Clin Pract.	72	142-147	2006
47	Hashimoto T, Nishio M, Sakai T, Fujimoto K, Sato N, Endo T, Koike T.	Acute schizophrenic symptoms as the initial manifestation of HIV infection that respond to highly active antiretroviral therapy.	Clinical Infectious Diseases.	42	1653-1655	2006
48	Furukawa S, Yasuda S, Amengual O, Horita T, Atsumi T, Koike T.	Protective effect of pravastatin on vascular endothelium in patients with System Sclerosis: a pilot study.	Ann Rheum Dis.	65 (8)	1118-1120	2006
49	Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, Kumano K, Minauchi K, Yamaguchi K, Takeda Y, Sato N, Koizumi K, Mukai M, Koike T.	Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma.	Eur J Haematol.	77	226-232	2006

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 住田 孝之

雑誌

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	Wakamatsu, E., Nakamura, Y., Matsumoto, I., Goto, D., Ito, S., Tsutsumi, A., and <u>Sumida, T.</u>	DNA microarray analysis of labial salivary glands from patients with Sjogren' s syndrome.	Ann. Rheum. Dis.		in press	
2	Yoshioka, H., Ito, S., Handa, S., Tomihata, S., Kose, K., Haishi, T., Tsutsumi, A., and <u>Sumida, T.</u>	Low-field compact magnetic resonance imaging system for the hand and wrist in rheumatoid arthritis.	J.Magn. Res. Ima.	23	370-376	2006
3	Wakamatsu, E., Matsumoto, I., Naito, Y., Goto, D., Mamura, M., Ito, S., Tsutsumi, A., and <u>Sumida, T.</u>	Overexpression of phosphorylated STAT- 1 α in the labial salivary glands of patients with Sjogren' s syndrome.	Arthritis Rheum.	54	3476- 3484	2006
4	Kori, Y., Matsumoto, I., Zhang, H., Yasukochi, T., Hayashi, T., Iwanami, K., Goto, D., Ito, S., Tsutsumi, A. and <u>Sumida, T.</u>	Characterization of Th1/Th2 type, glucose-6-phosphate isomerase reactive T cells in the generation of rheumatoid arthritis.	Ann. Rheum. Dis.	65	968-969	2006
5	Naito, Y., Matsumoto, I., Wakamatsu, E., Goto, D., Ito, S., Tsutsumi, A., and <u>Sumida, T.</u>	Altered peptide ligands regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjogren' s syndrome.	Ann. Rheum. Dis.	65	269-271	2006
6	Matsumoto, I., Hua, Z., Muraki, Y., Hayashi, T., Yasukochi, T., Kori, Y., Goto, D., Ito, S., Tsutsumi, A., and <u>Sumida, T.</u>	A functional variant of Fc γ receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose- 6-phosphate isomerase antibodies.	Arthritis Res. Ther.	7	1183- 1188	2005
7	Ohnishi, Y., Tsutsumi, A., Goto, D., Itoh, S., Matsumoto, I., Taniguchi, M., and <u>Sumida, T.</u>	TCRV α 14+ NKT cells function as effector T cells in mice with collagen- induced arthritis	Clin. Exp. Immunol.	141	47-53	2005
8	Naito, Y., Matsumoto, I., Wakamatsu, E., Goto, D., Tsutsumi, A., and <u>Sumida, T.</u>	Muscarinic acetylcholine receptor autoantibodies in patients with Sjogren' s syndrome.	Ann. Rheu. Dis.	64	510-511	2005
9	Takahashi, R., Tsutsumi, A., Ohtani, K., Muraki, Y., Goto, D., Matsumoto, I., Wakamiya, N., and <u>Sumida, T.</u>	Association of mannose binding lectin (MBL) gene polymorphism and serum MBL concentration with characteristics and progression of systemic lupus erythematosus.	Ann. Rheu. Dis.	64	311-314	2005
10	Muraki, Y., Matsumoto, I., Chino, Y., Hayashi, T., Suzuki, E., Goto, D., Ito, S., Murata, H., Tsutsumi, A., and <u>Sumida, T.</u>	GPI variants play a key role in the generation of anti-GPI Abs: possible mechanism of autoantibody production.	Biochem. Bioph. Res. Co.	60	1316- 1324	2004
11						
12						
13						
14						
15						
16						

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 亀田 秀人

書籍

	著者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
			書籍名	出版地	ページ
1	亀田秀人、竹内勤	関節リウマチ	山本一彦 編	日本臨床社	2005
			臨床免疫学 -基礎研究の進歩と最新の臨床-	大阪	261-266
2					
3					
4					
5					
6					
7					
8					
9					
10					
11					
12					
13					

研究成果の刊行に関する一覧表（平成16年度～平成18年度）

分担研究者氏名： 亀田 秀人

雑誌

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1	長澤逸人, 亀田秀人, 天野宏一, 竹内勲	関節リウマチ患者における血清マトリックスメタロプロテイナーゼ-3 (MMP-3) の臨床的意義	炎症・再生	25(1)	60-64	2005
2	Kameda H, Amano K, Sekiguchi N, Takei H, Ogawa H, Nagasawa H, Takeuchi T	Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients.	Mod Rheumatol	14	442-446	2004
3	Takeuchi T, Amano K, Kameda H, Abe T	Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases.	Allergology International	54(2)	191-202	2005
4	Kameda H, Ishigami H, Suzuki M, Abe T, Takeuchi T	Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor.	Clin Exp Immunol	144	335-341	2006
5	Sekiguchi N, Kameda H, Amano K, Takeuchi T	Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis.	Mod Rheumatol	16	85-91	2006
6	Takeuchi T, Amano K, Kameda H	Impact of TNF inhibitors on rheumatoid arthritis.	Inflammation and Regeneration	26	148-159	2006
7	Kameda H, Sekiguchi N, Nagasawa H, Amano K, Takei H, Suzuki K, Nishi E, Ogawa H, Takeuchi T	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.	Mod Rheumatol	16	381-388	2006
8	Kameda H, Okuyama A, Tamaru J-I, Itoyama S, Iizuka A, Takeuchi T	Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis.	Clin Rheumatol	in press		
9	Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T	Retrospective study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM).	Mod Rheumatol	17(1)	28-32	2007
10	亀田秀人, 竹内勲	TNFを標的とした慢性炎症性疾患の治療—抗TNF生物製剤による関節リウマチの寛解導入	医学のあゆみ	208(5)	336-342	2004
11	亀田秀人	関節リウマチ治療における生物学的製剤の役割	日本内科学会雑誌	94(10)	2084-2091	2005
12	亀田秀人, 竹内勲	生物学的製剤による関節リウマチの関節破壊抑制	The Bone	19(6)	67-72	2005
13	亀田秀人, 奥山あゆみ, 関口直哉	乾癬性関節炎に対するTNF阻害薬の効果	Medicina	43	972-975	2006
14	亀田秀人, 竹内勲	関節評価の実際と課題	リウマチ科	36	260-265	2006
15	亀田秀人, 竹内勲	エタネルセプト: 使い方と市販後調査	Mebio	23	52-58	2006
16	亀田秀人	エタネルセプトの使い方と注意すべき副作用	治療	89(2)	308-312	2007